BioSpace News Archive

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that under certain urgency provisions related to the COVID-19 pandemic it has received approval from the Spanish Drug Agency (AEMPS) to conduct a Phase II clinical trial with vafidemstat in seriously ill COVID-19 patients.

Rates Higher in New York City Metro Area Findings Mirror Studies Showing Prevalence Likely Far Higher than Official Reports

Nanoparticle Actinomycin formulation minimizes toxicity and enhances tolerability by slow release of drug to control Cmax in blood This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, United Kingdom, April 24, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, ann

Facial injectables have a large number of applications such as removal of wrinkles, scars treatment, acne treatment, and removal of dark circles. Besides these generalized applications, facial injectables are also used in lip augmentation, uplifting of eyebrows, thinning of the lips, and enhancement of the cheekbones, among others.

According to the American Sleep Association, around 50-70 million adults in the U.S. are suffering from sleep disorders, 48.0% of the U.S. adults report snoring, and approximately 5.9 million U.S. adults were diagnosed with obstructive sleep apnea (OSA).

The grant enables the hospital to quickly sanitize and reuse hoods worn by healthcare workers on the frontlines of the COVID-19 pandemic.

Buildings temporarily closed due to COVID-19 present an increased risk for waterborne pathogens like Legionella which can cause Legionnaires’ Disease.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the first quarter 2020 after 5:00 p.m. ET on Tuesday, May 5, 2020.

Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, conducted an observational real world study of more than 3,000 hospitalized COVID-19 patients and found that hypertension, the most common co-existing condition, does not have a major impact on survival from the infection when adjusted for age and other comorbid conditions.

Hebron Technology Co., Ltd. (“Hebron” or the “Company”) (Nasdaq: HEBT), a technology oriented enterprise group conducting business in the pharmaceutical equipment and engineering industry segment and financial service industry segment, today announced its financial results for the fiscal year ended December 31, 2019.